U.S. Generic Lipitor Sales Bring Ranbaxy In From Cold For Daiichi Sankyo
This article was originally published in PharmAsia News
Executive Summary
Just short of four years after Daiichi Sankyo bought Ranbaxy Laboratories, the acquisition has begun paying dividends, primarily because it got six months of exclusive U.S. rights to Pfizer’s best-selling cholesterol drug Lipitor (atorvastatin).